Ionis Pharmaceuticals Wins FDA Approval for First Alexander Disease Treatment

Key Points

• Ionis Pharmaceuticals received FDA approval for ZANVASTRO, the first disease-modifying treatment for Alexander disease, with a broad label covering children and adults.
• The approval was supported by a 54-patient trial showing statistically significant stabilization of gait, improvements in motor function among younger children, and reductions in plasma GFAP; most adverse reactions were mild to moderate.
• Ionis priced ZANVASTRO at $285,000 per quarterly dose and expects peak sales above $100 million, while focusing its U.S. launch on specialized treatment centers, patient identification and payer reimbursement.

Ionis Pharmaceuticals NASDAQ: IONS said the U.S. Food and Drug Administration has approved ZANVASTRO as the first and only disease-modifying treatment for Alexander disease, an ultra-rare, progressive neurological disorder caused by pathogenic variants in the GFAP gene.

The approval includes a broad label for children and adults with Alexander disease and arrived nearly three weeks ahead of the anticipated FDA decision date, according to Chief Executive Officer Brett Monia. The company said ZANVASTRO will be its first independently commercialized neurology launch.

Alexander disease affects the brain’s white matter and can cause progressive motor and cognitive dysfunction, loss of mobility and independence, and difficulty with swallowing, airway protection and purposeful movement. Symptoms commonly begin in infancy or childhood but can emerge at any age. The disease is estimated to affect roughly one in 1 million to 3 million people worldwide and is almost always fatal, Chief Development Officer Holly Kordasiewicz said.

Trial Results Support Broad Approval

The FDA approval was based on a controlled, integrated trial that combined first-in-human dose finding and pivotal-study components. The study enrolled 54 patients between ages 2 and 53, with most participants younger than 18 at enrollment.

The pivotal portion evaluated a 50-milligram quarterly intrathecal dose of ZANVASTRO. The primary endpoint assessed stabilization of gait speed in patients age 5 and older through the 10-meter walk test. Ionis said the study met that endpoint, demonstrating a statistically significant and clinically meaningful stabilization of gait among patients receiving the 50-milligram dose.

Secondary and exploratory measures also favored ZANVASTRO, according to the company. In patients ages 2 to 4, the drug improved gross motor function versus control on the Gross Motor Function Measure-88. ZANVASTRO also reduced plasma GFAP compared with control, which Ionis said provided evidence of target engagement and modulation of the disease’s underlying mechanism.

The company reported that most adverse reactions were mild to moderate, while serious adverse reactions occurred less frequently with ZANVASTRO than with control. Kordasiewicz said the safety profile was broadly similar between pediatric and adult patients.

ZANVASTRO is administered through intrathecal injection once every quarter. Ionis initially tested a lower 25-milligram quarterly dose in a small patient group to establish safety and pharmacokinetics before evaluating the approved 50-milligram regimen in a larger cohort.

U.S. Launch Targets Centers and Patient Identification

Ionis estimates that about 300 people in the U.S. are living with Alexander disease, with approximately half identified through medical claims. Many patients receiving supportive care are treated at about 12 leukodystrophy Centers of Excellence, which will be a central focus of the launch effort, Chief Global Product Strategy Officer Kyle Jenne said.

The company also plans to target approximately 25 key neurology centers and reach providers beyond the concentrated network of leukodystrophy centers to identify additional patients. The commercial effort will use a customer-facing field team, medical-affairs personnel, digital outreach and other omnichannel resources.

Ionis outlined four initial launch priorities:

• Transitioning patients in the clinical trial and expanded-access program to commercial product while maintaining continuity of care.
• Starting already diagnosed patients identified through ICD-10 codes and patient registries on treatment.
• Increasing disease awareness among physicians to identify additional patients.
• Working with payers to establish coverage and access.

Company executives did not disclose the number of patients in the open-label extension or expanded-access program. Monia said the majority of patients rolled into the open-label extension and all have continued, while the expanded-access program has drawn significant demand.

Jenne said patient transitions will take time because treatment is dosed quarterly and institutions must work through logistics and reimbursement requirements. Some patients may also be referred to local treatment centers, requiring identification of providers capable of administering intrathecal therapy.

Pricing, Reimbursement and Commercial Outlook

Ionis set ZANVASTRO’s launch price at $285,000 per dose. The drug is expected to be reimbursed primarily through patients’ medical benefits under a buy-and-bill model, meaning treatment institutions will purchase the product after receiving payer approval and then seek reimbursement.

Jenne said Ionis expects coverage to generally proceed through a medical-exception process on a patient-by-patient basis. The company has launched reimbursement and financial-assistance services under its Ionis Every Step program, including support for healthcare providers, patients and caregivers. Ionis said eligible commercially insured patients may reduce out-of-pocket costs to as little as zero dollars per prescription.

Ionis continues to estimate that ZANVASTRO could generate peak sales of more than $100 million. Jenne said reaching that level may take time because of the need to identify patients and establish treatment access.

Outside the U.S., commercial partner Recordati is expected to file for approval in the European Union and Japan next year, with further submissions planned afterward. Ionis also received a Rare Pediatric Disease Priority Review Voucher with the approval. Monia said the company has not determined whether it will use the voucher for an internal program or sell it, though its current priority is evaluating potential use across its wholly owned neurology pipeline.

About Ionis Pharmaceuticals (NASDAQ:IONS)

Ionis Pharmaceuticals, Inc is a biotechnology company focused on the discovery and development of RNA-targeted therapies designed to modulate gene expression. The company's proprietary antisense oligonucleotide (ASO) technology enables the selective binding of short synthetic strands of nucleic acids to messenger RNA (mRNA), thereby inhibiting or altering the production of disease-causing proteins. Ionis' pipeline spans a range of therapeutic areas, including neurological disorders, cardiovascular conditions, metabolic diseases and rare genetic disorders.

Since its founding in 1989 by Dr.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source